Eli Lilly and Company (LLY:NYSE) closed at $1,441.23 on November 13, 2026, up 1.10% on the day. The stock trades 1.3% below its 52-week high of $1,460.00 and 69.5% above its 52-week low of $850.51. Over the past year, it gained 39.5%. Eli Lilly and Company is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 12, 2025, LLY closed higher on 125 days (50%). Its best day was February 4, 2026 (+10.33%) and its worst was February 5, 2026 (-7.79%). The stock moved 10% or more in a single session 1 time.
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine headaches. Further, it provides animal health products, such as catt...
Find more stocks like LLY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.